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Abstract
Systematic identification of protein-drug interaction networks is crucial to correlate complex modes of drug action to
clinical indications. We introduce a novel computational strategy to identify protein-ligand binding profiles on a genome-
wide scale and apply it to elucidating the molecular mechanisms associated with the adverse drug effects of Cholesteryl
Ester Transfer Protein (CETP) inhibitors. CETP inhibitors are a new class of preventive therapies for the treatment of
cardiovascular disease. However, clinical studies indicated that one CETP inhibitor, Torcetrapib, has deadly off-target effects
as a result of hypertension, and hence it has been withdrawn from phase III clinical trials. We have identified a panel of off-
targets for Torcetrapib and other CETP inhibitors from the human structural genome and map those targets to biological
pathways via the literature. The predicted protein-ligand network is consistent with experimental results from multiple
sources and reveals that the side-effect of CETP inhibitors is modulated through the combinatorial control of multiple
interconnected pathways. Given that combinatorial control is a common phenomenon observed in many biological
processes, our findings suggest that adverse drug effects might be minimized by fine-tuning multiple off-target interactions
using single or multiple therapies. This work extends the scope of chemogenomics approaches and exemplifies the role that
systems biology has in the future of drug discovery.
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Introduction
Identification of protein-ligand interaction networks on a
proteome-wide scale is crucial to address a wide range of
biological problems such as correlating molecular functions to
physiological processes and designing safe and efficient therapeu-
tics [1]. Recent protein-ligand interaction studies have revealed
that protein targets involved in entirely different pharmacology
can bind similar small molecule drugs [2–4]. Large scale mapping
of polypharmacology interactions indicates that drug promiscuity
is a common phenomenon across the proteome [5]. It has been
found that approximately 35% of known drugs or leads were
active against more than one target. Moreover, a significant
number of promiscuous compounds (approximately 25%) have
observed activity in completely different gene families. Such drug
promiscuity presents both opportunities and challenges for
modern drug discovery. On one hand, it is possible to develop
high-efficacy drugs by inhibiting multiple targets [6] or to
reposition existing drugs to treat different diseases [7,8]; on the
other hand, the off-target effect may result in adverse drug
reactions that account for around one-third of drug failures during
development [9]. As a result, there is increasing interest in the
identification of multiple targets associated with a phenotype [6]
and in developing combinatorial therapies to boost clinical efficacy
[10]. Chemogenomics has emerged as a new discipline to
systematically establish target relationships based on the structural
and biological similarity of their ligands [3,11–18]. However, the
success of chemogenomics depends on the availability of
bioactivity data for the receptors and their associated ligands.
For new drug targets, such data are either insufficient or
unavailable. Further, the adverse drug reaction may involve
receptors that are not well characterized. Complementary to
chemogenomics methods, we have developed a chemical systems
biology approach to identifying off-target binding networks
through their ligand binding sites. The method requires 3D-
structure information for the protein but not the ligand, thereby
extending the scope of existing chemogenomics approaches.
Moreover, the identified off-target binding network is integrated
with the reconstructed biological pathways so that the effect of the
drug on the biological system can be understood at the system
level. In brief (see Methods for further details), our chemical
systems biology approach proceeds as follows: 1) The ligand
binding site of the primary target is extracted or predicted from a
3D experimental structure or homology model and characterized
by a geometric potential [19]. 2) Off-target proteins with a similar
ligand binding site to the primary target are identified across the
human structural genome using a Sequence Order Independent
Profile-Profile Alignment (SOIPPA) [20]. The atomic details of the
interactions between the drug and the putative off-targets from
step 2 are characterized using protein-ligand docking methods.
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are further investigated. 4) The identified panel of off-targets is
subject to structural and functional cluster analysis and incorpo-
rated into a network that includes multiple metabolic, signal
transduction, and gene regulation pathways. The first and second
steps have been implemented in the software package SMAP,
available from http://funsite.sdsc.edu.
In this paper, we apply this strategy to identify and analyze a
panel of unknown off-targets for Cholesteryl Ester Transfer
Protein (CETP) inhibitors. CETP inhibitors represent a new
preventive therapy for cardiovascular disease through raising HDL
cholesterol. However, clinical studies have revealed that one of the
CETP inhibitors, Torcetrapib, has deadly off-target effects as a
result of hypertension [21–25] and consequently was withdrawn
from phase III clinical trial. In contrast to Torcetrapib, another
CETP inhibitor JTT-705 does not have unwanted side-effects that
increases blood pressure [25]. In addition, JTT-705 is able to block
cell proliferation and angiogenesis through Ras and P38 kinase
pathways [26]. As will be shown, the multiple off-targets of these
CETP inhibitors identified here are involved in both positive and
negative control of stress regulation and immune response through
an interconnected metabolic, signal transduction and gene
regulation network. Our predictions are strongly correlated to
the observed clinical and in vitro observations, providing a
molecular explanation for the difference in side-effect profiles of
these two CETP inhibitors. These findings suggest that adverse
drug reactions might be modulated by the fine-tuning of the off-
target binding network and exemplify the role of systems biology
in the future of drug discovery.
Results
CETP off-target binding network computed for the
human structural genome
The ligand binding site of CETP (PDB id: 2OBD) is assumed to
be a long tunnel interacting with two cholesteryl oleates (2OB) and
two 1,2-dioleoyl-Sn-glycero-3-phosphocholines (PCW) molecules
in the native state (Fig. S1), however, the exact location of inhibitor
binding is unknown. Docking studies using the software Surflex
[27], eHits [28] and AutoDock [29] indicate that the CETP
inhibitors are able to bind to all four sites, with a slight preference
for the pocket occupied by PCW. Thus, all four sites were used to
search for the off-target binding sites of CETP inhibitors.
Although only approximately 15% of human proteins have
known 3D structures deposited in the Protein Data Bank (PDB)
[30] , the structural coverage of the human proteome increases to
57% if homologous proteins are included (e-value less than 1.0e-3
and aligned sequence lengths greater than 30 residues using a Blast
[31] search). The structural coverage is reduced to around 40% if
the aligned length is greater than 120 residues (Fig. S2). After
removing structures with redundant sequences (sequence identi-
ty=100%), 5,985 structures and models from the PDB were
selected for off-target search by SMAP. Besides bactericidal/
permeability increasing protein (PDB Id: 1ewf) that is classified in
the same fold and Pfam [32] family as CETP (FATCAT [33] p-
value=1.26e-11, RMSD=4.53), 273 off-fold structures are found
with similar binding sites to CETP (SMAP p-value less than 1.0e-
3). Reverse virtual screening of the 273 structures against JTT-
705, the smallest CETP inhibitor, was carried out with Surflex
[27] and eHits [28] (see Methods) to detect the binding capability
of these proteins. To reduce the impact of protein flexibility, the
complex structure, whenever available in PDB, is used for docking.
Proteins that have steric crashes with JTT-705 were removed from
the list and a panel of CETP off-targets consisting of 204 structures
was constructed for further study as shown in Table S1. The
majority of these off-targets have binding sites that match to one of
the two sites that are adjacent to PCW in CETP. Excluding
cytochrome P450s that bind drugs promiscuously, most of the
putative off-targets are involved in lipid/fatty acid transport or
binding, signal transduction pathways and immune response.
Based on both SMAP p-values and docking scores (p-value,1.0e-
3, Surflex score.3.50 and eHiTs score,24.50), six classes of
structure were consistently found at the top of the list: CD1B like
antigen recognition domains (CD1B); nuclear hormone receptor
ligand binding domains (NR); lipid transport proteins (LPTP); fatty
acid binding proteins (FABP); EF hand-like calcium binding
proteins (EF); and heme binding proteins (HEME). The first four
classes of proteins are able to bind cognate ligands similar to those
that bind to CETP, such as fatty acids, lipoproteins, and lipids
[34]. Although these putative off-targets do not have detectable
global structural similarities to CETP according to their CE Z-
scores (Fig. S3), they have local structural similarity and are related
to each other, forming an interconnected off-target network. As
shown in Fig. 1, 76% of the putative off-targets (154/204) form the
three largest clusters. The largest helix bundle cluster includes NR,
EF, HEME and other proteins (Fig. S4). In this paper, we focus on
the six selected classes of proteins and demonstrate how they
correlate to the clinical findings. Other putative off-targets are
subject to on-going computational and experimental studies.
Structural characterization of CETP off-targets
Most of the predicted ligand binding sites of CD1B, LPTP, and
FABP have a similar topology to that of CETP. The drug molecule
binds to a cavity formed by anti-parallel beta-sheets and capped by
other structural components such as a helix. The others, NR, EF,
and HEME all have alpha-helical architectures that are com-
pletely different from the secondary structure surrounding the
binding site of CETP. These differences illustrate the necessity of
tools like SMAP that can find local structural similarities even
when global similarity is non-existent. From a functional
perspective, it is not surprising that lipid binding proteins act as
off-targets for CETP inhibitors since they are required to bind
similar cognate hydrophobic ligands such as PCW. It is
noteworthy that glycolipid transfer protein, one of the lipid
binding proteins, has significant structural similarity to nuclear
Author Summary
Both the cost to launch a new drug and the attrition rate
during the late stage of the drug discovery and develop-
ment process are increasing. Torcetrapib is a case in point,
having been withdrawn from phase III clinical trials after 15
years of development and an estimated cost of US $800 M.
Torcetrapib represents a new class of therapies for the
treatment of cardiovascular disease; however, clinical
studies indicated that Torcetrapib has deadly side-effects
as a result of hypertension. To understand the origins of
these adverse drug reactions from Torcetrapib and other
related drugs undergoing clinical trials, we introduce a
systematic strategy to identify off-targets in the human
structural proteome and investigate the roles of these off-
targets in impacting human physiology and pathology
using biochemical pathway analysis. Our findings suggest
that potential side-effects of a new drug can be identified at
an early stage of the development cycle and be minimized
by fine-tuning multiple off-target interactions. The hope is
thatthis canreduce both the cost of drug development and
the mortality rates during clinical trials.
Off-Target Network and Drug Side Effects
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1.77e-3 when comparing one glycolipid transfer protein (PDB id:
1TFJ) with that of retinoid X receptor (PDB id: 1YOW), but the
RMSD is 9.82 A ˚ for a rigid superimposition. However, if the
components of these structures are allowed to twist, the RMSD
drops to 2.57 A ˚ when the helices surrounding the binding site are
well aligned (Fig. S5). The structural similarity between glycolipid
transfer protein and other all-helical proteins increases confidence
in our result that the lipid-activated nuclear receptor (NR) is one of
the major off-targets of CETP inhibitors.
Functional correlation of CETP with off-targets
We searched for possible functional correlations between CETP
and the putative off-targets using the iHOP [35] literature network
(http://www.ihop-net.org/UniPub/iHOP/in?dbrefs_1=NCBI_
LOCUSLINK__ID|1071). Several top-ranked off-targets ap-
pear in the same sentences with each other more than 3 times in
the literature. They include phospholipid transfer proteins,
nuclear receptors, including PPAR, major histocompatibility
complex class II that is similar to CD1B, apolipoprotein A-1,
and angiotension I converting enzyme.
The functional similarity between CETP and the off-targets is
further quantitatively measured using gene ontology (GO)
relationships found with the FunSimMat web server [36]
(http://funsimmat.bioinf.mpi-inf.mpg.de/index.php). From 204
off-targets, 148 structures had annotated GO terms and 94
structures had detectable similarities with a Resnik score [37]
larger than 0.0. Among these 94 structures, lipid transport/
binding proteins, CD1B, and nuclear hormone receptors were
ranked top, followed by globin-like, EF hand-like and other
proteins (Table S2).
Binding affinity similarity between CETP and off-targets
To further support our off-target predictions we conducted
docking studies on CETP and the identified off-targets, which also
provides insights into the molecular mechanisms of off-target
binding. It has been established that the binding affinity calculated
from docking programs is not necessarily reliable [38–40]. When
using an energy-based scoring function, the errors come
predominantly from the inaccurate parameterization of the
individual energy terms. We find that the docking scores for
CETP and its putative off-targets are linearly dependent on the
number of carbon atoms on the docked molecules because the
hydrophobic term dominates the scoring (Fig. S6). Based on this
observation we developed a procedure to minimize the systematic
error in the scoring function. Rather than considering the raw
docking score we used the z-score to represent the relative binding
affinity. The z-score is derived from a large number of random
drug-like molecules and is dependent on both the number of
carbon atoms in the ligand and the nature of the protein binding
site. A large negative z-score indicates a high probability of true
binding. Based on this procedure, the normalized docking scores
(NDS) of the six classes of off-targets are listed in Table 1. These
data indicate that binding of CETP inhibitors to putative off-
targets is indeed statistically significant. Furthermore, the vector
distance of the carbon atom size dependent average docking score
for CETP and the majority of off-targets is less than 1.0 (Table S3).
This implies that the ligands are able to bind to CETP and to the
Figure 1. The three largest clusters of the off-target network formed from their global structural similarities. Each node in the graph
represents one off-target as found in supplemental material Table S1. Two nodes are connected by an edge if their global structures are similar
(measured by a CE [104] z-score larger than 4.0).
doi:10.1371/journal.pcbi.1000387.g001
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binding affinity differences are less than 1.0, which is the standard
deviation of docking scores (see Methods). Finally, the correlation
of ligand binding profiles between CETP and its off-targets [4] are
relatively high (Table S3 and Fig. S7).
Importantly, the binding profiles for the three CETP inhibitors
(Torcetrapib, Anacetrapib, and JTT-705) are different from each
other across the panel of off-targets. JTT-705 is the most
promiscuous inhibitor. In contrast, Torcetrapib failed to dock
into some of the off-targets, and Anacetrapib is suitable to be
docked into the least number of off-targets. The difference
between their off-target binding profiles can be partly explained
by their different complexity [41] and sizes. The molecular
volumes of JTT-705, Torcetrapib and Anacetrapib are 407.31,
498.42, and 527.28 A ˚ 3, respectively. As shown in Table 1 the
estimated volume of the off-target binding pockets varies greatly.
Thus, the smallest ligand, JTT-705, can be accommodated in all of
these pockets, but the larger-sized Torcetrapib and Anacetrapib
are difficult to fit into the smaller sized pockets. It could be argued
that the failure in docking Torcetrapib and Anacetrapib into the
smaller sized pockets is because the induce fit of the receptor is not
explicitly modeled. However, for most of the NRs, both antagonist
and agonist conformations are tested. Thus it is less likely that the
unfitness of Torcetrapib and Anacetrapib for some of the off-
targets is a result of not specifically considering induced fit in the
docking calculation. The different off-target binding profiles of
these CETP inhibitors have significant implications for the
observed side-effects, as discussed subsequently.
Incorporation of the off-target binding network into
biological pathways
By incorporating the predicted off-targets into biological
pathways it is possible for us to correlate the predicted off-target
interactions with the observed pleotropic effects of Torcetrapib,
Anacetrapib and JTT-705. Among them, the negative effect of
Torcetrapib on blood pressure in phase III clinical trials could be
deduced. Also deducible was an explanation for the increased
death from infection and cancer [21]. Conversely, JTT-705 has
gotten encouraging safety results from phase II clinical trials and
no side-effects of hypertension have been observed thus far.
Similar positive results are observed for Anacetrapib during phase
I clinical trials. It should be noted that at this time that JTT-705
and Anacetrapib are in clinical trials involving only a small
number of patients during short term studies. Results from long
term studies are needed to confirm the absence of negative effects
for these two drugs. In addition, JTT-705 is found to be able to
block cell proliferation and angiogenesis through Ras and P38
kinase pathways [26]. To illustrate these findings, using a survey of
the literature, we constructed a hierarchical biological network
that connects drugs, off-targets, pathways and clinical observa-
tions. Using this network we could explore the implications of
administering CETP inhibitors on different pathways through
Table 1. Binding site volumes and normalized docking scores (NDS) of CETP inhibitors for CETP and six classes of putative off-
targets.
Target Class Protein PDB ID
Binding Site
Volume (A ˚ 3) Normalized Docking Score
Torcetrapib Anacetrapib JTT-705
CETP 2OBD
$ 1084.2 25.6024
* 24.6705
* 21.9644
#
NR Retinoid X receptor (agonist) 1YOW
$ 1420.5 25.5803
* 24.1922
* 20.9344
#
PPARd (agonist) 1Y0S
$ 1313.2 23.8703
* 23.8384
* 21.5662
#
PPARa (agonist) 2P54
$ 1059.4 24.0828
* 6.6785 23.0660
*
PPARa (antagonist) 1KKQ
$ 1012.6 23.8847
* 23.8554
* 20.9725
#
PPARc (agonist) 1ZEO
$ 726.5 23.9838
* 6.0096 22.0316
*
LXRa (agonist) 2ACL
$ 1155.0 5.7793 6.3052 20.6900
#
LXRb (agonist) 1UPV 1553.5 5.0882 5.5450 21.7543
#
Vitamin D receptor (agonist) 1IE8
$ 879.7 5.7622 6.1759 21.1761
#
Vitamin D receptor (antagonist) 2ZMH
$ 1055.8 5.1326 23.2234
* 20.8868
#
Glucocorticoid receptor (agonist) 1P93
$ 819.0 5.5504 6.1432 22.0131
*
Glucocorticoid receptor (antagonist) 1NHZ
$ 990.5 22.1235
* 23.2125
* 21.1673
#
LPTP Glycolipid transfer protein 1TFJ
$ 987.4 20.9839
# 22.1587
* 21.3249
#
Phosphatidylcholine transfer protein 1LN1 1860.1 27.3050
* 29.1032
* 21.0794
#
Phosphatidylinositol transfer protein 2A1L
* 2271.7 24.0881
* 26.0708
* 21.7366
#
GM-2 activator 2AG9 955.0 24.0254
* 23.8265
* 23.6934
*
FABP Fatty acid binding protein 2NNQ
* 743.3 3.3521 6.8334 22.3356
*
CD1B CD1B receptor 1GZP 1056.4 22.0899
* 26.1531
* 21.3424
#
EF Troponin C 1DTL 1992.0 23.7771
* 23.6403
* 22.9955
*
HEME Cytochrome complex 1PP9 2963.0 23.8702
* 27.0825
* 22.2745
*
Human cytoglobin 1V5H 1022.2 23.4827
* 21.8246
# 22.3848
*
The predicted binding affinities are grouped with different symbols: * represents strong binding affinity (NDS,22.0).
#relatively strong (0.0.NDS.22.0), and others represent less likely binding due to the steric crashes between the ligand and the protein (NDS.0.0), respectively.
$indicates that Cystine appears in the binding site and may form disulfide bonds with JTT705.
doi:10.1371/journal.pcbi.1000387.t001
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network consists of several interconnected metabolic, signal
transduction, and gene regulation pathways. Each component of
the network is separately shown in Fig. 2, Fig. 3, Fig. 4, and Fig.
S9, and is discussed in detail in the following sections. It is notable
that several predicted off-targets, especially the nuclear hormone
receptors, are essential components in the network, involved in
both positive and negative controls of several cellular systems.
Nuclear hormone receptors are known as lipid-activated tran-
scription factors that play key roles in lipid metabolism,
inflammatory processes and the hormone system. The regulatory
controls of our predicted nuclear hormone receptors are on
pathways involved in hypertension, inflammation and cancer
development. Torcetrapib, Anacetrapib and JTT705 showed
different binding affinities to these receptors and thus different
clinical outcomes resulting from the combinational responses of
these receptors in related pathways.
Combinatorial control of nuclear hormone receptors in
hypertension. As shown in Fig. 2, the effects of the three CETP
inhibitors on blood pressure can be explained through their
influence on the Renin-Angiotension-Aldosterone System (RAAS),
the main system for blood pressure regulation. When the RAAS
system is too active, blood pressure becomes dangerously high.
Several nuclear receptors highly ranked in our off-target list are
involved in the regulation of this system, including proxisome
proliferator-activated receptor (PPAR), retinoid X receptor
(RXR), liver X receptor (LXR) and Vitamin D receptor (VDR)
[42]. As positive regulators, activation of PPAR, RXR and LXR
increases gene expression of angiotensinogenase and then up-
regulates RAAS, resulting in high blood pressure and increased
aldosterone secretion. In contrast, VDR has a negative control on
RAAS. Activation of VDR will balance the up-regulation effect of
PPAR, RXR and LXR on blood pressure.
According to the normalized docking scores (Table 1), Torce-
trapib, Anacetrapib and JTT-705 show distinctly different binding
profiles to these nuclear receptors, consistent with their differing
involvement in hypertension. To avoid inaccuracy in the docking
calculation, three different categories (strong, relatively strong and
weak) were used to estimate the binding affinity, instead of direct
comparison of individual docking scores. It is noteworthy that the
weak binding (large positive normalized docking score) is due
mainly to the steric crashes between the CETP inhibitors and the
receptor. As a result the inhibitors cannot fit into the binding
pockets of these receptors. Interaction between the three CETP
inhibitors and nuclear receptors are shown in Fig. 2 with different
colors illustrating the type of interaction. When the three CETP
inhibitors are docked as agonists to these nuclear hormone
receptors the stronger binding affinity to the panel of positive
regulators (PPAR, LXR and RXR) indicates stronger up-
regulation of RAAS and higher risk of hypertension; stronger
binding affinity to the negative regulator VDR implies a lower risk
of hypertension. It is clearly shown in Fig. 2 that JTT-705 has
relatively strong binding affinity not only to the positive regulators
but also as an agonist to the negative regulator, implying the ability
Figure 2. Effects of Torcetrapib, Anacetrapib and JTT-705 in regulating the RAAS system through the combinational control of
nuclear hormone receptors. The red, purple, and blue lines between inhibitors and off-targets indicate strong, relatively strong, and weak binding
affinities, respectively. The brown and black lines between off-targets and pathways or clinical indications represent positive and negative regulation,
respectively. A. Regulation control of nuclear hormone receptors on RAAS system. B. Binding profile of Torcetrapib on nuclear hormone receptors. C.
Binding profile of Anacetrapib on nuclear hormone receptors. D. Binding profile of JTT-705 on nuclear hormone receptors.
doi:10.1371/journal.pcbi.1000387.g002
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RAAS and consequently a lesser chance to cause hypertension. In
contrast to JTT-705, Torcetrapib binds more strongly to the active
conformations of the positive regulators and leads to increased
blood pressure through up-regulation of RAAS. Limited by its
larger size, Anacetrapib can only bind to RXR and PPARd in
their active conformations and PPARa and VDR in their inactive
conformations (listed in Table 1), even though it is in the same
structural class as Torcetrapib. Thus, Anacetrapib has less effect
on both the positive and negative control of blood pressure and its
negative effect on blood pressure regulation may be less than
Torcetrapib. Even though the detailed mechanism for the side-
effect of hypertension caused by Torcetrapib is still unknown and
the different binding profiles of the three CETP inhibitors needs
experimental verification, our observations are consistent with the
current clinic trial data from the three CETP inhibitors and the
predicted off-targets provides information for future use in drug
optimization.
Combinatorial control of nuclear hormone receptors in
inflammation. The effects of CETP inhibitors on inflammation
are shown in Fig. 3. Activation of nuclear hormone receptors such
as PPAR, LXR, GCR and RXR regulates gene expression
associated with inflammation through different mechanisms
[34,43] and consequently reduces the inflammatory response.
For example, NF-kB plays a key role in regulating the immune
response to infection. PPARa/c, LXRa/b and GCR can block
the NF-kB pathway by directly binding to AP1 and NF-kB [44–
48], acting downstream of NF-kB binding to DNA [49], or by
competing for limited amounts of co-activators [50]. There are
other examples to show the PPAR induced trans-repression of
inflammatory response genes [51,52]. PPARc/d can also function
as transcriptional regulators of monocyte phenotypic differenti-
ation by promoting expression of target genes involved in M2
Figure 3. Effects of Torcetrapib, Anacetrapib and JTT-705 on inflammation through combinational control of nuclear hormone
receptors. The color and line schema are the same as those in Fig. 2. A. Regulation control of nuclear hormone receptors on inflammatory system. B.
Binding profiles of Torcetrapib on nuclear hormone receptors. C. Binding profile of Anacetrapib on nuclear hormone receptors. D. Binding profile of
JTT-705 on nuclear hormone receptors.
doi:10.1371/journal.pcbi.1000387.g003
Figure 4. Effects of Torcetrapib, Anacetrapib and JTT-705 on
cancer through combinational control of nuclear hormone
receptors. The color and line schema are the same as those in Fig. 2. A.
Regulation control of nuclear hormone receptors on cancer system. B.
Binding profiles of Torcetrapib on nuclear hormone receptors. C.
Binding profile of Anacetrapib on nuclear hormone receptors. D.
Binding profile of JTT-705 on nuclear hormone receptors.
doi:10.1371/journal.pcbi.1000387.g004
Off-Target Network and Drug Side Effects
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generate anti-inflammatory products [53–55]. Thus, the overall
picture of activation of these nuclear hormone receptors involved
in inflammatory response suggests that they have interesting anti-
inflammatory effects. The binding profiles of Torcetrapib,
Anacetrapib and JTT-705 to these nuclear hormone receptors
(listed in Table 1 and shown in Fig. 3) indicate that JTT-705 has a
broader control over the inflammation system to reduce the
inflammatory response.
The regulatory effect of nuclear hormone receptors on
cancer. NF-kB regulates genes involved in cell proliferation and
cell survival and hence is an interesting drug target in cancer
treatment. Inhibition of NF-kB can potentially halts tumor
progression and eliminate tumors [56,57]. As discussed above,
activation of PPARa/c, LXRa/b and GCR will block the NF-kB
pathway and thus prevent cancer. Of the three CETP inhibitors
only JTT-705 is predicted to bind to these receptors and hence
have the ability to control cell proliferation and tumor progression
(Fig. 4).
Recent experiments have shown that PPARa and PPARc can
induce extracellular signal-regulated kinase (Erk) and/or p38
phosphorylation and then activate the MAPK/Erk signaling
pathway [58,59]. This pathway is involved in the action of most
nonnuclear oncogenes and participates in cancer development
[60]. Interestingly, JTT-705 was shown to block cell proliferation
through the activation of the p38 MAPK pathway [26], but the
mechanism for how JTT-705 induces p38 MAPK activation is still
unclear. Our results suggest a possible hypothesis (Fig. 5). JTT-705
could trigger the p38 MAPK pathway through its interaction with
PPARa/c and thus has the potential to prevent cell proliferation
and cancer.
Regulatory effects of other identified off-targets. Effects
of PPAR and RXR are also regulated by fatty acid binding
proteins (FABP) [61]. FABP can function as an intracellular
chaperone to transport fatty acids and drugs into the nucleus and
directly interact with PPAR [62]. The cooperation between FABP
and PPAR will enhance the activities of PPAR in gene
transcription regulation [63,64]. FABP can also interact with
hormone-sensitive lipases to potentially modulate their catalytic
activity and thereby integrates several signaling networks that
control inflammatory response potentially through the JNK/
inhibitor of kappa kinase (IKK) and IKK–nuclear factor-kB (NF-
kB) pathway [61]. According to the calculated docking scores, only
JTT-705 can bind to FABP and further regulate hypertension and
inflammation.
Another type of highly ranked off-target, CD1, can also be
directly related to the side- effect of infection through its function
as an antigen-presenting protein in the immune system. T cells will
recognize antigens presented by CD1 proteins and activate a cell-
mediated immune response against microbial infections [65].
Docking results show that all three drugs have a strong binding
affinity to CD1, suggesting an impact on antimicrobial immunity
and host response to infection.
Other putative off-targets such as ubiquinol-cytochrome-c
reductases, globin-like proteins, EF hand-like calcium binding
proteins (EFs), and LPTP are also directly or indirectly associated
with hypertension, inflammation, and/or cancer. Recent studies
suggest that ubiquinol-cytochrome-c reductase expression is
indirectly regulated by steroid hormones in response to hyperten-
sion [66]. Further, as one of the key protein components in the Q-
cycle [67,68] it contributes to the regulation of cell death and
repair [69] and may also be related to cancer and infection. It is
interesting that hemoglobin has been found in non-hematopoietic
organs such as the kidney acting as an anti-oxidative defense agent
[70]. It is also involved in the activation of KCl cotransporter
activity [71,72], which may affect the regulation of blood pressure.
EFs modulate vascular function through Ca
2+ homeostasis and
nitric oxide. It has also been observed that the lack of S100A1 (an
EF protein) expression could lead to hypertension [73]. EFs also
have effects on transcription factors. They not only indirectly
regulate the activity of transcription factors through their
phosphorylation/dephosphorylation in response to Ca
2+ levels
but also directly control the transcriptional activity of the tumor
suppressor p53 through interactions with its regulatory sequences
[74]. It is not surprising that LPTP is one of CETP’s off-targets
because they bind to the same or similar cognate ligands and are
involved in lipid metabolism. However, the biological functions of
phosphatidylinositol/phosphatidylcholine transfer proteins (PITPs)
have not been well characterized [75,76]. They may play a role in
Figure 5. The anti-proliferation effect of JTT-705 through
activation of PPARa/c and the p38 MAPK pathway. Solid lines
show relationships established with experimental evidence. Red dash
lines show our hypothesis for how JTT-705 induces the activation of the
p38 MAPK pathway. Color and line schema are the same as those in
Fig. 2.
doi:10.1371/journal.pcbi.1000387.g005
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blood pressure through the release of noradrenaline and
adrenaline [77]. Interactions between the three CETP inhibitors
and these predicted off-targets show potential additional contri-
butions to the side-effects of hypertension, inflammation and
cancer.
In summary, most of the putative off-targets for CETP
inhibitors are involved in interconnected lipid metabolism and
signaling networks which activate or mediate various biological
process such as hypertension, stress regulation [78], immune
response [79] and cell death [80]. Our predications are consistent
with current clinical studies on all three CETP inhibitors,
highlighting the interrelationship of multiple biological processes
involved in hypertension, infection and cancer. These results call
for further experimental validation.
Discussion
Roles of combinatorial control in modulation of side-
effects of CETP inhibitors
In vitro, in vivo and clinical studies indicate that CETP inhibitors
exhibit pleotropic effects in humans through the interaction with
unknown off-targets. We have identified a panel of proteins that
likely bind to CETP inhibitors leading to the observed clinical
indications. The putative off-target interactions are consistent with
existing experimental data and provide insights into the molecular
mechanisms of the side-effect profile of CETP inhibitors. Drug
promiscuity depends not only on the similarity of ligand binding
pockets in the related proteins but also the complexity of the drug
itself [41]. In general, smaller molecules are able to bind more
targets. The same trend has been predicted for CETP inhibitors;
the smallest JTT-705 is the most promiscuous and the largest,
Anacetrapib, is the least promiscuous. However, in contrast to
conventional wisdom that implies the more specific the binding the
lesser the side-effects, the most promiscuous inhibitor, JTT-705,
does not cause the side-effect of hypertension that is observed in
the more specific Torcetrapib. Considering the regulation of blood
pressure by NRs, it is possible that JTT-705 acts as an antagonist
of NRs to down-regulate aldosterone. However, our results suggest
that CETP inhibitors prefer binding to the agonist rather than the
antagonist conformation of the NR. Experimental evidence also
implies that JTT-705 actually activates NR to mediate Ras and
p38 kinase pathways [26]. Thus, it is more likely that the side-
effect of CETP inhibitors is modulated by a combination of
biological controls involved in many physiological processes such
as cell proliferation [81], inflammation and hypertension. In other
words, JTT-705 is involved in activation of NRs that contribute to
both positive and negative controls of aldosterone. Although
Torcetrapib is more specific and binds less off-targets than JTT-
705, it only activates those NRs that up-regulate RAAS resulting
in hypertension. To fully understand how small molecules can
modulate physiological or pathological processes through such
combinatorial control, it is necessary to simulate the dynamic
properties of the biological system. To this end, it is a critical first
step to identify all of the putative molecular receptors involved in
the biological process and to connect them into a logical integrated
protein-ligand interaction network.
Advantages and limitations of the methodology
The chemical systems biology approach developed here is
limited by available protein structures that currently only cover
approximately 50% of the human proteome, although the
structural coverage of the human proteome will steadily increase
with progress in structural genomics [82] and conventional
structure determination. As a result, some potential off-targets
may be missed because they are not included in the screening. In
addition to establishing functional relationships between proteins
using their sequences, structures and functional sites, there are
significant efforts to relate drug targets to their ligands through
chemical genomics analysis [12]. However, the chemical genomics
approach is restricted by the availability of bioactivity data. When
exploring off-targets that cover the whole human proteome, this
limitation becomes obvious since only a small number of target
families explored by pharmaceutical companies are in the
bioactivity database [5]. Thus our method is complementary to
existing chemical genomics approaches. Drug-target networks will
be greatly expanded by combining chemical genomics data and a
structural genome-wide off-target analysis. Several studies have
attempted to extend the target-based method to the domain-based
model through similar sequence motifs or global structures [83]. In
this study we further expand the scope of the chemical genomics
approach beyond sequence and fold similarity by searching for
similar ligand binding sites. Hence a ligand binding site-based
approach will provide an ever improving way to generate a
candidate list of proteins participating in interconnected biochem-
ical pathways and to establish their relationships to biological
processes. It is hoped that these approaches will eventually provide
the foundation for the in silico simulation of the influence of small
molecules on biological systems. In the interim it is noted that the
analysis of incomplete networks is still invaluable in making new
discoveries in biomedicine as exemplified by several recent studies
[3,11].
Besides SMAP used in this study, a number of web servers for
ligand binding site search are available, for example, SiteEngine
[84], SitesBase [85,86], CavBase [87–89], SuMo [90], PdbSiteS-
can [91], eF-Site [92,93], pvSOAR [94], and pevoSOAR [95].
Compared with these servers, SMAP has several distinguishing
features making it particularly suitable for identifying off-targets on
a structural genome-wide scale. First, SMAP does not require
prior knowledge of both the location and the boundary of the
ligand binding site. Instead, whole proteins are scanned to find the
most similar local patch in the spirit of local sequence alignment
such as the Smith-Waterman algorithm [96]. This feature makes
SMAP appropriate for practical problems since typically the
boundary of the ligand binding site is not clearly defined or
depends on the ligand in the complex structure. Second, SMAP
integrates geometric, evolutionary and physical information into a
unified similarity score akin to a sequence alignment score.
However, unlike conventional sequence alignment, the SMAP
alignment is sequence order independent; a necessary requirement
when comparing local binding sites. Third, because SMAP uses
the reduced structure representation, it is not sensitive to structural
uncertainty and flexibility. Thus SMAP can be applied to
homology models and handle flexible ligand binding sites. Finally,
we have developed a probability model to efficiently estimate the
statistical significance of the binding site similarity. The model
allows us to reliably identify similar ligand binding sites in a high
throughput fashion. Despite these advantages of SMAP, it is
expected that the best results will come from the combination of
different tools as demonstrated by many studies in bioinformatics
and molecular modeling.
Despite the success of ligand binding search algorithms in
protein function prediction and drug design [2,4,20,87,88,95,97–
99] currently no algorithm can retrieve all of the binding sites that
bind a cognate ligand such as ATP. However, in the context of
searching for off-targets of drug molecules, the actual number of
false negatives may be limited based on the nature of the drug.
False negatives in the ligand binding site search are due mainly to
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physical and geometric changes in the binding site. Most existing
drugs are designed to selectively inhibit an exquisite target. They
are more rigid and less adaptable to the changing environment of
the binding site than the cognate ligand. For example, a protein
kinase ATP competitive inhibitor is designed to inhibit only the
ATP binding site of the protein kinase, not that of other
superfamilies such as P-loop hydrolases. On the other hand,
although rational drug design may take the same cognate ligand
binding site into account, it rarely explores the cross-reactivity
between binding sites that are not naturally designed for the same
cognate ligand but are able to bind the same drug. Studies by
others have shown that the drug binding site can be considered as
a negative image of the drug to screen compound database [100]
or vice versa to model the drug binding site [101]. Hence ligand
binding site similarity search is a valuable tool to identify off-
targets that accommodates only the drug molecule but not
necessarily all proteins that bind to the same cognate ligand across
gene families. In general, the chemical systems biology approach
developed in this paper is specific in identifying potential off-
targets for drug-like molecules and could be used in concert with
experimental design employing in vitro screening, in vivo screening
and clinical trials.
Implications for drug discovery and development
Even with the current limited structural coverage of the human
proteome, our predications are able to provide a testable
hypothesis as to the suitability of a lead compound prior to
conducting a clinical trial. Thus our findings have implications for
drug discovery and development. In contrast to the conventional
drug discovery process in which drug leads are optimized to
reduce promiscuous binding, the possible combinatorial control of
aldosterone regulation by CETP inhibitors suggests that adverse
drug effects can be minimized through fine tuning of multiple off-
target interactions. Although it is desirable for a drug to bind the
primary target in a highly specific way, this is difficult to achieve
considering the inherent similarity among protein binding pockets
within and across gene families. Moreover, many biological
process involve combinatorial control to provide redundancy and
homeostasis [102]. In such cases it becomes very difficult to
modulate the systems behavior by inhibiting or activating only one
single target protein. Thus, a multiple-target approach [6] and
combination therapy [10] have been actively pursued to boost
clinical efficacy in the treatment of diseases such as cancer and
diabetes. However, these combined approaches are rarely
systematic with the purposeful intent of developing therapeutics
that bind to a primary target to treat the disease, but at the same
time are considered to bind to desirable off-targets that modulate
side-effects. In some cases this combined goal is achieved
serendipitously as would seem to be the case for JTT-705. Instead
of using a single molecule, it may be more feasible to use multiple
components to treat a disease state and at the same time to reduce
drug side-effects. Different from conventional combination
therapy where all of components target disease related proteins,
here only a subset of the molecules are directly therapeutic, other
molecules serve the purpose of reducing side-effects by targeting
non-disease related proteins. We speculate that many drugs which
failed due to off-target effects can be rescued by this target-off-
target combination therapy. For example, it is expected that the
side-effect of Torcetrapib can be reduced by introducing molecules
that binds to molecular components involved in the negative
control of aldosterone regulation. Such therapies can be only
rationally designed by exploring the system properties of the
biological network.
Methods
Binding site similarity search on a genome scale
5,985 structures or models that cover approximately 57% of the
human proteome were searched against CETP (PDB id: 2obd)
ligand binding sites using the sequence order independent profile-
profile alignment (SOIPPA) algorithm [20]. A new statistical
model was introduced to the original approach to estimate the
significance of the alignment score [103]. In brief, the alignment
score for a given alignment length is fitted to an extreme value
distribution (EVD):
Ps wS ðÞ ~1{exp {exp {Z ðÞ ðÞ ð 1Þ
Where:
Z~ S
2{m
    
s ð2Þ
where S is the raw SOIPPA similarity score. m and s are fitted to
the logarithm of N, which is the alignment length between two
proteins:
m~a ln N ðÞ
2zb
 ln N ðÞ zc ð3Þ
s~d
 ln N ðÞ
2ze ln N ðÞ zf ð4Þ
Six parameters a, b, c, d, e, and f are 5.963, 215.523, 21.690,
3.122, 29.449, and 18.252 for the McLachlan similarity matrix
used in this study, respectively.
Using this statistical model, 276 off-targets are identified with p-
values less than 1.0e-3.
Reverse screening of the human structural proteome
The putative 276 off-targets are subject to further investigation
using more computationally intensive protein-ligand docking.
After removing three structures with the same fold as CETP,
JTT-705, the smallest CETP inhibitor, is docked to the remaining
273 structures using two commonly used fast docking programs,
Surflex 2.1 [27] (default setting) and eHits 6.2 [28] (fastest setting).
69 structures with a Surflex docking score smaller than 0.0 or an
eHits score larger than 0.0 are considered to be difficult to fit JTT-
705 due to significant steric crashes (and hence the other two
inhibitors based on size) and are removed from the putative off-
target list. The remaining 204 structures are subject to further
investigation using the docking software AutoDock4.0 [29] and
other more computationally intense methods as described below.
Global structure similarity network of off-targets
An all-against-all global structural similarity analysis between
the 204 putative off-targets was computed using CE [104]. A
graph is constructed with each of the structures as a node. An edge
is formed between two nodes if their CE z-score is larger than 4.0
(a superfamily level similarity) [104].
Volume of the binding pocket
The volume of the binding pocket is computed using the CASTp
server [105] (http://sts-fw.bioengr.uic.edu/castp) with default settings.
Normalized docking score
Drug-like molecules are downloaded from ZINC (http://zinc.
docking.org) [106]. From this database, six sets of molecules are
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carbon atoms, respectively; each set includes 100 molecules. These
molecules are docked to CETP and its putative off-targets using
eHiTs [28] and AutoDock4.0 [29]. The correlation of the docking
score to the number of carbon atoms is derived from linear
regression for each of the protein receptors. From the linear fitting
curve, the average docking score for molecules with a certain
number of carbon atoms can be estimated.
Based on the fitted average docking score, a normalized docking
score DS is calculated as a z-score:
DS~ Si{mi ðÞ =s ð5Þ
Where Si is the raw docking score for the molecule with i carbon
atoms, mi is the fitted average docking score for the number of
carbon atoms i, s is the standard deviation, which is not dependent
on the size of molecules and is approximately 1.0 in all cases.
Vector distance of the average docking score
The vector distance of the average docking score D between
CETP and its off-targets is calculated from the average values of
the docking scores for randomly selected molecules with fixed
numbers of 5, 10, 15, 20, 25 and 29 carbon atoms as follows:
D~
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
X
N
SCETP{Soff
   2
,
N
v u u t ð6Þ
where SCETP and Soff are the average values of carbon atom size
dependent docking scores to CETP and its off-targets, respectively.
Conclusion
In this case study, we identify a panel of off-targets of CETP
inhibitors using a chemical systems biology approach. All of the
identified off-targets belong to different protein superfamilies from
the primary target, but are structurally and functionally related,
being mainly involved in lipid metabolism, immune response and
signaling networks. Among them, CD1, nuclear hormone
receptors and lipid transport proteins are the most likely off-
targets with highly consistent results from multiple resources
including functional correlation, ligand binding site similarity,
hydrophobic scales, and predicted binding affinities. Moreover,
the elucidated off-target effects from these proteins are strongly
correlated to clinical and in vitro observations. Their combinatorial
control of biological process plays a key role in the modulation of
the adverse drug effect of CETP inhibitors. This study
demonstrates that a chemical systems biology approach, which
systematically explores protein-ligand interactions on a genome-
wide scale and incorporates them into biological pathways, will
provide us with valuable clues as to the molecular basis of cellular
function. At the same time, it will help to transform the
conventional single-target-single-drug drug discovery process to a
new multi-target-multi-molecule paradigm.
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